1. |
Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer, 1972, 29(6): 1705-1712.
|
2. |
Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol, 2014, 165(3): 358-363.
|
3. |
Cheah CY, Campbell BA, Seymour JF. Primary breast lymphoma. Cancer Treat Rev, 2014, 40(8): 900-908.
|
4. |
Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol, 2008, 19(2): 233-241.
|
5. |
Jennings WC, Baker RS, Murray SS, et al. Primary breast lymphoma: the role of mastectomy and the importance of lymph node status. Ann Surg, 2007, 245(5): 784-789.
|
6. |
Talwalkar SS, Miranda RN, Valbuena JR, et al. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol, 2008, 32(9): 1299-1309.
|
7. |
Uesato M, Miyazawa Y, Gunji Y, et al. Primary non-Hodgkin’s lymphoma of the breast: report of a case with special reference to 380 cases in the Japanese literature. Breast Cancer, 2005, 12(2): 154-158.
|
8. |
Ou CW, Shih LY, Wang PN, et al. Primary breast lymphoma: a single-institute experience in Taiwan. Biomed J, 2014, 37(5): 321-325.
|
9. |
Yhim HY, Kim JS, Kang HJ, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer, 2012, 131(1): 235-243.
|
10. |
Brogi E, Harris NL. Lymphomas of the breast: pathology and clinical behavior. Semin Oncol, 1999, 26(3): 357-364.
|
11. |
段明辉, 曹欣欣, 蔡华聪, 等. 14 例原发乳腺淋巴瘤患者临床分析. 中华血液学杂志, 2014, 35(10): 918-921.
|
12. |
Yoshida S, Nakamura N, Sasaki Y, et al. Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol, 2005, 18(3): 398-405.
|
13. |
Fukuhara S, Watanabe T, Munakata W, et al. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. Eur J Haematol, 2011, 87(5): 434-440.
|
14. |
Ryan GF, Roos DR, Seymour JF. Primary non-Hodgkin’s lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma, 2006, 6(4): 337-341.
|
15. |
Yhim HY, Kang HJ, Choi YH, et al. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer, 2010, 10: 321.
|
16. |
罗必华, 黄建清, 闫子勋, 等. 21 例原发乳腺淋巴瘤患者疗效及预后分析. 中华血液学杂志, 2015, 36(4): 277-281.
|
17. |
Jeanneret-Sozzi W, Taghian A, Epelbaum R, et al. Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer. 2008. 8: 86.
|
18. |
Caon J, Wai ES, Hart J, et al. Treatment and outcomes of primary breast lymphoma. Clin Breast Cancer, 2012, 12(6): 412-419.
|
19. |
Avilés A, Castañeda C, Neri N, et al. Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica, 2007. 92(8): 1147-1148.
|
20. |
Wong WW, Schild SE, Halyard MY, et al. Primary non-Hodgkin lymphoma of the breast: the Mayo clinic experience. J Surg Oncol, 2002, 80(1): 19-25; discussion 26.
|
21. |
Dao AH, Adkins RB, Glick AD. Malignant lymphoma of the breast: a review of 13 cases. Am Surg, 1992, 58(12): 792-796.
|
22. |
Roschewski M, Dunleavy K, Wilson WH. Diffuse large B cell lymphoma: molecular targeted therapy. Int J Hematol, 2012, 96(5): 552-561.
|
23. |
Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood, 2009, 113(24): 6069-6076.
|
24. |
Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol, 2011, 29(6): 690-697.
|
25. |
Zhang LH, Kosek J, Wang M, et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol, 2013, 160(4): 487-502.
|
26. |
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer, 2011, 117(22): 5058-5066.
|
27. |
Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 2010, 115(13): 2578-2585.
|
28. |
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol, 2013, 31(1): 88-94.
|
29. |
Gupta E, Accurso J, Sluzevich J, et al. Excellent outcome of immunomodulation or bruton’s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Rare Tumors, 2015, 7(4): 6067.
|
30. |
Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia, 2015, 29(7): 1578-1586.
|
31. |
Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol, 2015, 16(6): 704-715.
|